Alerts will be sent to your verified email
Verify Email
ONESOURCE
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
OneSource Specialty Pharma is India’s first specialty pharma pure-play Contract Development and Manufacturing Organization (CDMO). With comprehensive experience in the development and manufacturing of specialized drug-device combinations, the company can provide consistent support and quality throughout the full life cycle of complex combination product.
Onesource Specialty major competitors are Astrazeneca Pharma I, Eris Lifesciences, Alembic Pharma, Pfizer, Sai Life Sciences, Wockhardt, Piramal Pharma.
Market Cap of Onesource Specialty is ₹21,542 Crs.
While the median market cap of its peers are ₹22,952 Crs.
Onesource Specialty seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Mar May Jun Aug | |||||||||||||||||
| Investor Presentation | Aug | |||||||||||||||||
| Conference Call | Mar Jun | |||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
